CLSD Clearside Biomedical, Inc.: institutional ownership and insider trading
1 funds reported holding $74.4K of Clearside Biomedical, Inc. in their latest 13F filings; in Q4 2025 funds net bought $0, with 0 new positions and 3 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $3.33M and net income of −$26.0M.
CLSD revenue and earnings
- Quarter ended Sep 30, 2025: revenue $201K, net income −$5.97M, EPS -1.14
- Quarter ended Jun 30, 2025: revenue $492K, net income −$4.50M, EPS -0.06
- Quarter ended Mar 31, 2025: revenue $2.33M, net income −$8.22M, EPS -0.11
- Quarter ended Dec 31, 2024: revenue $306K, net income −$7.31M, EPS 1.34
Largest institutional holders of CLSD
- Northeast Financial Consultants Inc — $74.4K
Recent CLSD insider trades
- Feb 24, 2025: Thorp Clay bought 15,000 shares ($13.8K)
- Nov 1, 2024: Chong Ngai Hang Victor bought 36,500 shares ($36.5K)
5%+ owners
- WHITMORE BRADFORD T: 8.6% (Schedule 13G/A, filed Mar 4, 2025)
- Stephen Boyd Wiles: 5.2% (Schedule 13G, filed Apr 1, 2025)